Barbara Weber - Feb 1, 2022 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Executive Officer, Director
Signature
/s/ Douglas Barry, as attorney-in-fact
Stock symbol
TNGX
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/3/2022, 03:30 PM
Previous filing
Oct 27, 2021
Next filing
Jun 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNGX Stock Option (Right to Buy) Award $0 +625K $0.00 625K Feb 1, 2022 Common Stock 625K $9.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter.